ArticleJournal of medical economics

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.

Olalekan O Oluwole et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.